REG - ValiRx PLC - ValiRx establishes US office in Boston, MA <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

05/11/2015 07:01

RNS Number : 6237E
ValiRx PLC
05 November 2015
ValiRx Plc
("ValiRx"or "theCompany")
"VALIRX ESTABLISHES US OFFICE IN BOSTON, MASSACHUSETTS & STRENGTHENS ITS US ADVISORY TEAM"
London, UK, 5th November 2015: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that it has established US operations in Cambridge, Boston, Massachusetts and has strengthened its US advisory team following the appointment of industry specific advisors in the US.
The US operation is being formed to encourage and facilitate greater interaction with academic, clinical and business leaders in ValiRx's areas of oncological development. Our new office in Kendall Square, Cambridge, close by the Massachusetts Institute of Technology ("MIT") will be advantageous to the business as we look to expand our co-operation with biotech and pharma players in the US market.
Dr Satu Vainikka, CEO of ValiRx, commented:"ValiRx's expansion into the US is part of our strategy to strengthen our investor base and to take advantage of close proximity to the biggest biotech market in the World. With VAL201 progressing in the Phase I/II trial and VAL401 on the verge of entering a Phase IIb Clinical Trial, we also felt it important to support our drug development programme by strengthening the team, particularly in the US. It is an exciting time for the group and I look forward to benefiting rapidly from our US presence."
*** ENDS ***
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 3008 4416
Dr Satu Vainikka
www.valirx.com
Cairn Financial Advisers LLP (Nominated Adviser)
Tel: +44 (0) 20 7148 7900
Liam Murray / Avi Robinson

Northland Capital Partners Limited (Broker)
Tel: +44 (0) 20 7382 1100
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Abigail Wayne (Broking) 

Peckwater PR
Tel: +44 (0) 7879 458 364
Tarquin Edwards
tarquin.edwards@peckwaterpr.co.uk
Notes for Editors 
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed onthe Alternative Investment Market ("AIM") of the London StockExchange in October 2006.
The Company has a pipeline ofother therapeutic drugs, which are currently progressing towards clinicaltrials. The product focus is in the targeted analysis and treatment of cancer,but thetechnologies can be applied to other fields as well, such as neurologyand inflammatory diseases. It actively manages projectswithin its portfolio as a trading company. The ValiRx business model spreads the risks of life science technologydevelopment by minimizing financial exposure andrunning a set of projects todefined commercial endpoints. This maximizes returns to shareholders by adding value at the earlier stages where value increases per investment unit are thegreatest.
The Company operates through thefollowing divisional companies:
1. ValiPharma is the therapeuticsdivision, with two embedded technologies primarily directed at the treatment ofcancers.
2. ValiFinn is the biomarkers anddiagnostic development division. ValiRxacquired through its ValiFinn subsidiary, the complimentary TRAC technologylater in the year to strengthen the portfolio.
3. ValiSeek is a joint venturebetween ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentiallyother indications.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCPKQDPKBDBBDK